@article{7fa8ec436f6f4984b9dfe8427b53e67f,
title = "Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.",
author = "Jerome Galon and Bernhard Mlecnik and Florence Marliot and Fang-Shu Ou and Bifulco, \{Carlo Bruno\} and Alessandro Lugli and Inti Zlobec and Rau, \{Tilman T.\} and Arndt Hartmann and Masucci, \{Giuseppe V.\} and Eva Zavadova and Pam Ohashi and Roehrl, \{Michael H. A.\} and Yutaka Kawakami and Toshihiko Torigoe and Ascierto, \{Paolo Antonio\} and Franco Marincola and Sargent, \{Daniel J.\} and Fox, \{Bernard A.\} and Franck Pages",
note = "3500 Background: Mounting evidence indicates an enhanced lymphocytic reaction as an informative prognostic indicator in colon cancer (CC). The IM methodology has been defined to quantify the in situ immune infiltrate. Methods: A Society for Immunotherapy of Cancer-led international consortium of 23 pathology expert centers from 17 countries was initiated to evaluate the standardized IM assay in routine clinical settings.",
year = "2016",
month = may,
day = "20",
doi = "10.1200/JCO.2016.34.15\_SUPPL.3500",
language = "American English",
volume = "34",
journal = "Journal of Clinical Oncology",
}